Fortress Biotech, Inc. (FBIO)

NASDAQ: FBIO · IEX Real-Time Price · USD
1.850
+0.110 (6.32%)
Feb 26, 2024, 4:00 PM EST - Market closed
6.32%
Market Cap 33.63M
Revenue (ttm) 80.97M
Net Income (ttm) -82.32M
Shares Out 18.38M
EPS (ttm) 4.31
PE Ratio 0.43
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 333,783
Open 1.740
Previous Close 1.740
Day's Range 1.728 - 1.870
52-Week Range 1.240 - 13.500
Beta 1.51
Analysts Strong Buy
Price Target 55.00 (+2,872.97%)
Earnings Date Mar 28, 2024

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 187
Stock Exchange NASDAQ
Ticker Symbol FBIO
Full Company Profile

Financial Performance

In 2022, FBIO's revenue was $75.74 million, an increase of 10.11% compared to the previous year's $68.79 million. Losses were -$86.58 million, 33.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $55.0, which is an increase of 2,872.97% from the latest price.

Price Target
$55.0
(2,872.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea

Other symbols: DERM
7 weeks ago - GlobeNewsWire

Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

7 weeks ago - GlobeNewsWire

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29 Provides additional capital for general corporate purposes including funding to s...

Other symbols: DERM
7 weeks ago - GlobeNewsWire

Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

2 months ago - GlobeNewsWire

Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.

Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones

2 months ago - GlobeNewsWire

Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics

Sentynl receives worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101 copper histidinate CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease; rolling...

2 months ago - PRNewsWire

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023 On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023

Other symbols: DERM
2 months ago - GlobeNewsWire

Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023

3 months ago - GlobeNewsWire

Fortress Biotech Announces Closing of $10.0 Million Public Offering

MIAMI, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

3 months ago - GlobeNewsWire

Fortress Biotech Announces Pricing of $10.0 Million Public Offering

MIAMI, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

3 months ago - GlobeNewsWire

Fortress Biotech Announces Launch of Proposed Public Offering

MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...

3 months ago - GlobeNewsWire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023

Other symbols: DERM
3 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide...

Other symbols: DERM
4 months ago - GlobeNewsWire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission ...

Other symbols: DERM
4 months ago - GlobeNewsWire

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1

Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for whic...

4 months ago - GlobeNewsWire

Fortress Biotech Announces Reverse Stock Split

MIAMI, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and c...

5 months ago - GlobeNewsWire

Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference

Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.

5 months ago - GlobeNewsWire

Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference

MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing o...

6 months ago - GlobeNewsWire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses ...

Other symbols: DERM
6 months ago - GlobeNewsWire

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023

7 months ago - GlobeNewsWire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023

Other symbols: DERM
7 months ago - GlobeNewsWire

Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023

MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or...

7 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET

Other symbols: DERM
7 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corpor...

Other symbols: DERM
7 months ago - GlobeNewsWire

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues

Other symbols: DERM
8 months ago - GlobeNewsWire